SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-011037
Filing Date
2020-06-12
Accepted
2020-06-11 19:20:52
Documents
64
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 455398
2 ex31-1.htm EX-31.1 15461
3 ex32-1.htm EX-32.1 7128
  Complete submission text file 0001493152-20-011037.txt   3623988

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE endv-20200331.xml EX-101.INS 553741
5 XBRL SCHEMA FILE endv-20200331.xsd EX-101.SCH 62831
6 XBRL CALCULATION FILE endv-20200331_cal.xml EX-101.CAL 51934
7 XBRL DEFINITION FILE endv-20200331_def.xml EX-101.DEF 209145
8 XBRL LABEL FILE endv-20200331_lab.xml EX-101.LAB 393312
9 XBRL PRESENTATION FILE endv-20200331_pre.xml EX-101.PRE 282012
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 20958419
SIC: 2834 Pharmaceutical Preparations